Abstract 3888: Next generation cell engineering: the Jump-In cell engineering platform

Abstract

Abstract The stable introduction of genetic material into cell lines has become one of the most widely used methods since its introduction more than 3 decades ago. Cell engineering has become an indispensable tool for a wide range of areas in Life Science, such as cell biology, physiology, In-vivo modeling, drug discovery and bioproduction. However, most cell engineering strategies currently employed for the generation of stable cell lines require substantial commitment in respect to time, FTE hours and resources. In addition, most cell lines are generated by relying on random integration of genetic material into the genome, which typically results in a wide range of expression levels within a cell population. For these reasons the frequent generation of engineered cell lines is in general cumbersome and unpredictable. Life Technologies recently developed and validated the Jump-In™ cell engineering platform, a novel gene targeting technology based on R4 integrase mediated site specific homologous recombination. This technology allows the targeted integration of genetic material into a specific pre-engineered site, which by design reduces the effort required for generation of stable cell lines compared to standard methods. Isogenic expression from a defined genomic locus provides the ideal solution for comparative analysis of gene families, isotypes or orthologs. This technology was applied to two widely used cellular backgrounds, HEK293 and CHO-K1. We used these cellular backgrounds as case studies to demonstrate how this technology can be applied to rapidly generate engineered cell lines for a variety of cell based assay applications, including reporter assays for pathway analysis, GPCR activity assays and analysis of protein post-translational modifications. In summary, Jump-In™ technology enables researchers to accelerate the development of cellular assays by greatly reducing the amount of time and resources required for the upfront cell engineering process. For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3888. doi:1538-7445.AM2012-3888